SV2A

SV2A
Available structures
PDB	Ortholog search: PDBe RCSB
List of PDB id codes
	4V11
Identifiers
Aliases	SV2A, SV2, synaptic vesicle glycoprotein 2A
External IDs	OMIM: 185860; MGI: 1927139; HomoloGene: 32237; GeneCards: SV2A; OMA:SV2A - orthologs
Gene location (Human)
Chr.	Chromosome 1 (human)
End	149,917,844 bp
Gene location (Mouse)
Chr.	Chromosome 3 (mouse)
End	96,102,837 bp
RNA expression pattern
	Top expressed in
	Brodmann area 10; ; lateral nuclear group of thalamus; ; paraflocculus of cerebellum; ; pars compacta; ; frontal pole; ; superior frontal gyrus; ; middle temporal gyrus; ; postcentral gyrus; ; primary visual cortex; ; pars reticulata;
	Top expressed in
	lateral geniculate nucleus; ; lateral hypothalamus; ; mammillary body; ; ventral tegmental area; ; pontine nuclei; ; primary visual cortex; ; superior colliculus; ; cerebellar cortex; ; dorsal tegmental nucleus; ; ventromedial nucleus;
	More reference expression data
	More reference expression data
Gene ontology
Molecular function	transmembrane transporter activity; transporter activity; protein kinase binding; signaling receptor activity;
Cellular component	membrane; synaptic vesicle; cell-cell junction; neuromuscular junction; plasma membrane; synapse; presynaptic active zone; cell junction; endoplasmic reticulum; cytoplasmic vesicle; integral component of membrane; integral component of synaptic vesicle membrane; synaptic vesicle membrane; neuron projection; dendrite; soma; glutamatergic synapse; GABA-ergic synapse;
Biological process	cellular calcium ion homeostasis; transmembrane transport; neurotransmitter transport; regulation of gamma-aminobutyric acid secretion; chemical synaptic transmission; signal transduction; synaptic vesicle priming;
	Sources:Amigo / QuickGO
Orthologs
	9900
	64051
	ENSG00000159164
	ENSMUSG00000038486
	Q7L0J3
	Q9JIS5
	NM_014849; NM_001278719; NM_001328674; NM_001328675
	NM_022030
	NP_001265648; NP_001315603; NP_001315604; NP_055664
	NP_071313
	Wikidata
View/Edit Human	View/Edit Mouse

Synaptic vesicle glycoprotein 2A (SV2A) is a transmembrane protein belonging to a family of keratan sulfate proteoglycans, located on the synaptic vesicles of mammalian neuronal and endocrine cells. It's encoded by the SV2A gene.^[5]^[6]^[7]

SV2A is the most widely expressed isoform of the SV2 family (which also includes the SV2B and SV2C proteins) found in all brain regions.^[8] The role of the SV2 proteins is not well understood, however they are thought to be involved in regulating vesicular processes.^[8]

The SV2A protein is a target of the anti-epileptic drugs (anticonvulsants) levetiracetam and brivaracetam^[9] but it is not clear how these drug affect SV2A activity.^[10]

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000159164 – Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000038486 – Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Bajjalieh SM, Peterson K, Linial M, Scheller RH (Mar 1993). "Brain contains two forms of synaptic vesicle protein 2". Proceedings of the National Academy of Sciences of the United States of America. 90 (6): 2150–4. Bibcode:1993PNAS...90.2150B. doi:10.1073/pnas.90.6.2150. PMC 46043. PMID 7681585.
^ Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM (Dec 1999). "Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)". Proceedings of the National Academy of Sciences of the United States of America. 96 (26): 15268–73. Bibcode:1999PNAS...9615268C. doi:10.1073/pnas.96.26.15268. PMC 24809. PMID 10611374.
^ "Entrez Gene: SV2A synaptic vesicle glycoprotein 2A".
^ ^a ^b Rossi, Rachele; Arjmand, Shokouh; Bærentzen, Simone Larsen; Gjedde, Albert; Landau, Anne M. (2022-04-28). "Synaptic Vesicle Glycoprotein 2A: Features and Functions". Frontiers in Neuroscience. 16: 864514. doi:10.3389/fnins.2022.864514. ISSN 1662-4548. PMC 9096842. PMID 35573314.
^ Ulloa CM, Towfigh A, Safdieh J (2009). "Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures". Neuropsychiatric Disease and Treatment. 5: 467–76. doi:10.2147/ndt.s4844. PMC 2747386. PMID 19777068.
^ Contreras-García, Itzel Jatziri; Cárdenas-Rodríguez, Noemí; Romo-Mancillas, Antonio; Bandala, Cindy; Zamudio, Sergio R.; Gómez-Manzo, Saúl; Hernández-Ochoa, Beatriz; Mendoza-Torreblanca, Julieta Griselda; Pichardo-Macías, Luz Adriana (2022-04-13). "Levetiracetam Mechanisms of Action: From Molecules to Systems". Pharmaceuticals. 15 (4): 475. doi:10.3390/ph15040475. ISSN 1424-8247. PMC 9030752. PMID 35455472.

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000159164 – Ensembl, May 2017

[refGRCm38Ensembl-2] GRCm38: Ensembl release 89: ENSMUSG00000038486 – Ensembl, May 2017

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid7681585-5] Bajjalieh SM, Peterson K, Linial M, Scheller RH (Mar 1993). "Brain contains two forms of synaptic vesicle protein 2". Proceedings of the National Academy of Sciences of the United States of America. 90 (6): 2150–4. Bibcode:1993PNAS...90.2150B. doi:10.1073/pnas.90.6.2150. PMC 46043. PMID 7681585.

[pmid10611374-6] Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM (Dec 1999). "Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)". Proceedings of the National Academy of Sciences of the United States of America. 96 (26): 15268–73. Bibcode:1999PNAS...9615268C. doi:10.1073/pnas.96.26.15268. PMC 24809. PMID 10611374.

[entrez-7] "Entrez Gene: SV2A synaptic vesicle glycoprotein 2A".

[:0-8] Rossi, Rachele; Arjmand, Shokouh; Bærentzen, Simone Larsen; Gjedde, Albert; Landau, Anne M. (2022-04-28). "Synaptic Vesicle Glycoprotein 2A: Features and Functions". Frontiers in Neuroscience. 16: 864514. doi:10.3389/fnins.2022.864514. ISSN 1662-4548. PMC 9096842. PMID 35573314.

[pmid19777068-9] Ulloa CM, Towfigh A, Safdieh J (2009). "Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures". Neuropsychiatric Disease and Treatment. 5: 467–76. doi:10.2147/ndt.s4844. PMC 2747386. PMID 19777068.

[10] Contreras-García, Itzel Jatziri; Cárdenas-Rodríguez, Noemí; Romo-Mancillas, Antonio; Bandala, Cindy; Zamudio, Sergio R.; Gómez-Manzo, Saúl; Hernández-Ochoa, Beatriz; Mendoza-Torreblanca, Julieta Griselda; Pichardo-Macías, Luz Adriana (2022-04-13). "Levetiracetam Mechanisms of Action: From Molecules to Systems". Pharmaceuticals. 15 (4): 475. doi:10.3390/ph15040475. ISSN 1424-8247. PMC 9030752. PMID 35455472.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]